Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.
about
Nonsense mutation-associated Becker muscular dystrophy: interplay between exon definition and splicing regulatory elements within the DMD gene.Interplay between DMD point mutations and splicing signals in Dystrophinopathy phenotypes.A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy.Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells.Targeting RNA to treat neuromuscular disease.New developments in the use of gene therapy to treat Duchenne muscular dystrophy.Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment.Optimal classification for the diagnosis of duchenne muscular dystrophy images using support vector machines.Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD)Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy.Antisense oligonucleotides: the next frontier for treatment of neurological disorders.Myoblots: dystrophin quantification by in-cell western assay for a streamlined development of Duchenne muscular dystrophy (DMD) treatments.RNA-Seq Analysis of an Antisense Sequence Optimized for Exon Skipping in Duchenne Patients Reveals No Off-Target Effect.NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
P2860
Q34221402-331F6D59-66C0-4CDB-AF0A-18265F02D195Q34639835-7553152F-CDDA-41B3-82A9-1521C11B957DQ36114216-7E21AB1E-859B-4419-B17A-EE9094CB2811Q36179776-622087B2-030A-444E-B4E3-0CCF45DFE6EAQ36278519-A0C1C61A-3E72-4DA0-9905-9C20EBFD7BBDQ37909000-EBC2E6F2-A002-4340-9336-C58A5DE25A02Q38168863-8F854F7E-CEF5-42D5-AB01-2BC3252362A6Q38340328-DC16E5EE-DCC5-45E6-98AB-851766572143Q40420554-02160A6C-9909-430A-BEA8-DBF10E192C15Q42122236-E9123A3D-15BF-4D4E-80E4-69237A41971CQ45945952-28CC9A0A-210F-4318-A5EF-EBD89691AF25Q47158837-D33B9C56-F96C-40CC-A67A-7F09CB7E240EQ47344432-661969C5-E8E4-4580-A13F-255184EC1344Q47584439-F2736A6E-A972-476F-A134-B3B5C70C8283Q49196789-850EA5DD-EB36-43D1-AD11-297DCA32849FQ58549842-041A35DC-3B8E-451E-A2BF-E7B55E4433D3
P2860
Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Comparative analysis of antise ...... ns for future clinical trials.
@en
Comparative analysis of antise ...... ns for future clinical trials.
@nl
type
label
Comparative analysis of antise ...... ns for future clinical trials.
@en
Comparative analysis of antise ...... ns for future clinical trials.
@nl
prefLabel
Comparative analysis of antise ...... ns for future clinical trials.
@en
Comparative analysis of antise ...... ns for future clinical trials.
@nl
P2093
P50
P1476
Comparative analysis of antise ...... ns for future clinical trials.
@en
P2093
Carl Adkin
Christa L de Winter
George Dickson
Ian R Graham
Jennifer E Morgan
Linda J Popplewell
Steve D Wilton
P304
P356
10.1016/J.NMD.2009.10.013
P577
2010-01-15T00:00:00Z